Allo-hMSCs
Phase 1Small molecule
Allo-hMSCs is one of 88 small molecule programs targeting Hypoplastic Left Heart Syndrome. It is currently in Phase 1.
3
Indications
4
Total Trials
0
Active Trials
87
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
386 competitors in Cystic Fibrosis
#DrugCompanyPhaseTrials
1Calciferol
Alnylam PharmaceuticalsPreclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Actimmune
HHorizon Therapeutics Ireland DAC
Preclinical
Proair HFA
GGlaxo Dba Glaxosmithkline
Preclinical
Aztreonam Lysine
GileadPreclinical
Amitiza
SSucampo Pharma Americas, LLC
Preclinical
Capromorelin
UUniversity of Aarhus
Preclinical
Advil
KKenvue Brands
Preclinical
Tums
OtsukaPreclinical
Serevent
GGlaxo Dba Glaxosmithkline
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hypoplastic Left Heart Syndrome1 trial
Treatment Resistant Depression1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Allo-hMSCs. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- JJoshua M Hare